United States · Bill · HR
H.R. 4629 (116th)
Star Rating for Biosimilars Act
Introduced
8 October 2019
Last action
—
Status
Sponsor introductory remarks on measure. (CR H8232)
Sponsors
—
Subjects
Discovery layer
Source updated
3 January 2025
Summary
Star Rating for Biosimilars Act This bill requires the Centers for Medicare & Medicaid Services (CMS) to establish quality measures regarding biosimilar biological products under the five-star performance rating system for Medicare Advantage plans. The measures must assess the level of access that plans provide to covered biosimilars, including with respect to formularies, cost-sharing, and utilization management. The CMS must also incorporate such measures into similar rating systems for plans under the Medicare prescription drug benefit.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
3 official files
Introduced in House (text)
Introduced in House (text)
Introduced in House · EN · 8 October 2019
Introduced in House (PDF)
Introduced in House · EN · 8 October 2019
Introduced in House
summary · EN · 8 October 2019
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/116th-congress/house-bill/4629
- Open data entity: https://api.congress.gov/v3/bill/116/hr/4629